Oxford University Press

SHERPA: Yellow

People

  1. Drilon
    Drilon
  2. Motzer
    Motzer
  3. Mellinghoff
    Mellinghoff
  4. Shuman
    Shuman
  5. Rosenblum
    Rosenblum
  6. Dunkel
    Dunkel
  7. Karajannis
    Karajannis
  8. Saltz
    Saltz
  9. Souweidane
    Souweidane
  10. Panageas
    Panageas

Groups

  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)
  7. Department of Pathology and Laboratory Medicine (415)
  8. Gastrointestinal Oncology Service (386)
  9. Genitourinary Oncology Service (367)
  10. Tow Center for Developmental Oncology (TCDO) (352)
Search Within
Formats
  1. Journal Article (2107)
  2. Meeting Abstract (2072)
  3. Book Section (192)
  4. Review (92)
  5. Editorial (84)
  6. Guidelines (36)
  7. Correspondence (26)
  8. Book Whole (18)
  9. Conference Paper (15)
  10. Research Letter (10)
Groups
  1. Department of Medicine (1995)
  2. Solid Tumor Oncology Division (1624)
  3. GSK Faculty (765)
  4. Survivorship Research (639)
  5. Population Sciences Research Program (615)
  6. Epidemiology and Biostatistics (465)

More Groups

People
  1. Lisa De Angelis (119)
  2. Alexander Drilon (108)
  3. Robert Motzer (96)
  4. Ingo Mellinghoff (93)
  5. Stewart Shuman (88)
  6. Marc Rosenblum (87)

More People

Years
  1. 2025 (105)
  2. 2024 (304)
  3. 2023 (320)
  4. 2022 (331)
  5. 2021 (323)
  6. 2020 (325)

More Years

Publications
  1. Annals of Oncology (1670)
  2. Neuro-Oncology (846)
  3. JNCI: Journal of the National Cancer Institute (485)
  4. Nucleic Acids Research (210)
  5. Clinical Infectious Diseases (138)
  6. American Journal of Clinical Pathology (106)

More Publications

Results (4652)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Outcomes by histology and prior therapy with lenvatinib plus pembrolizumab vs treatment of physician's choice in patients with advanced endometrial cancer (Study 309/KEYNOTE-775)
    Meeting Abstract

    Colombo, N.; Lorusso, D.; Casado Herráez, A.; Santin, A. D.; Colomba, E.; Miller, D. S.; Fujiwara, K.; Pignata, S.; Floquet, A.; Monk, B. J.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Association between biomarkers and clinical outcomes of lenvatinib (L) + pembrolizumab (P) in advanced endometrial cancer (EC): Results from KEYNOTE-146/study 111
    Meeting Abstract

    Makker, V.; Taylor, M. H.; Aghajanian, C.; Cohn, A. L.; Brose, M. S.; DiSimone, C.; Cao, A.; Suttner, L.; Loboda, A.; Cristescu, R.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Atezolizumab monotherapy in cisplatin-ineligible patients with previously untreated metastatic urothelial carcinoma: 5-year response and survival analysis from the phase II IMvigor210 study (cohort 1)
    Meeting Abstract

    Rosenberg, J. E.; Galsky, M. D.; Balar, A. V.; Loriot, Y.; Necchi, A.; Hoffman-Censits, J.; Srinivas, S.; Drakaki, A.; Javery, A.; Nelson, B.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Randomized, open-label, 3-arm phase III study comparing MK-1308A + lenvatinib and pembrolizumab (pembro) + belzutifan + lenvatinib versus pembro + lenvatinib as first-line (1L) treatment for advanced clear cell renal cell carcinoma (ccRCC)
    Meeting Abstract

    Rini, B. I.; Plimack, E. R.; Powles, T. B.; Voss, M. H.; Gurney, H. P.; Silverman, R.; Perini, R.; Rodriguez-Lopez, K.; Choueiri, T. K.
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Relacorilant, a selective glucocorticoid receptor modulator, in combination with nab-paclitaxel improves progression-free survival in patients with recurrent platinum-resistant ovarian cancer: A 3-arm, randomized, open-label, phase II study
    Meeting Abstract

    Colombo, N.; Nguyen, D. D.; Fleming, G. F.; Grisham, R. N.; Lorusso, D.; Van Gorp, T.; Oaknin, A.; Pashova, H. I.; Grauer, A.
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • First-line nivolumab + cabozantinib vs sunitinib in patients (pts) with advanced renal cell carcinoma (aRCC) in subgroups based on prior nephrectomy in the CheckMate 9ER trial
    Meeting Abstract

    Porta, C. G.; Burotto, M.; Suarez Rodriguez, C.; Bourlon, M. T.; Hsieh, J.; Shah, A. Y.; Hamzaj, A.; Bedke, J.; Pook, D.; Kessler, R.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Matching-adjusted indirect comparison (MAIC) of health-related quality of life (HRQoL) of nivolumab plus cabozantinib (N+C) vs pembrolizumab plus axitinib (P+A) in previously untreated advanced renal cell carcinoma (aRCC)
    Meeting Abstract

    Porta, C. G.; Motzer, R.; Ejzykowicz, F.; Blum, S. I.; Hamilton, M.; May, J. R.; Huo, S.; Kral, P.; Ivanescu, C.; Choueiri, T. K.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • Analysis of hard-to-treat subgroups from EV-301: A phase III trial of enfortumab vedotin (EV) vs chemotherapy for previously treated advanced urothelial carcinoma
    Meeting Abstract

    Rosenberg, J. E.; Powles, T.; Sonpavde, G. P.; Loriot, Y.; Duran, I.; Lee, J. L.; Matsubara, N.; Vulsteke, C.; Castellano, D.; Mamtani, R.; more...
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • SAABR: Single arm phase II study of abiraterone + atezolizumab + GnRH analog and stereotactic body radiotherapy (SBRT) to the prostate in men with newly diagnosed hormone-sensitive metastatic prostate cancer (mHSPC)
    Meeting Abstract

    Rathkopf, D. E.; Decker, B.; Schum, P.; McBride, S.
    Annals of Oncology (2021)

    Fulltext@MSK | Save
  • PSMAddition: A phase III trial to compare treatment with (177)Lu-PSMA-617 plus standard of care (SOC) versus SOC alone in patients with metastatic hormone-sensitive prostate cancer
    Meeting Abstract

    Tagawa, S. T.; Sartor, O.; Saad, F.; Sakharova, O.; de Bono, J.; Feng, F.; Fizazi, K.; Morris, M. J.
    Annals of Oncology (2021)

    Fulltext@MSK | Save